Study of IMC-003 for pulmonary arterial hypertension
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with PAH (Group 1) through a specific heart test (right heart catheterization).
- Your PAH symptoms make you feel short of breath during daily activities (WHO class II or III).
- You can walk between 150 and 450 meters in 6 minutes (tested twice, a week apart).
- You have been on your current PAH medicines for at least 3 months without changes.
- You are not pregnant and agree to use effective birth control during the study and for 16 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
Hear when a new Pulmonary Arterial Hypertension PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.